Robert Eubanks, director of healthcare and life sciences with West Monroe, discuses the changes in how vaccines and drug therapies are developed and distributed as a result of the COVID-19 pandemic.

Yossi Sheffi, Elisha Gray II Professor of Engineering Systems & Director of the MIT Center for Transportation and Logistics, discusses his new book, The New (Ab)Normal: Reshaping Business and Supply Chain Strategy Beyond Covid-19.

Blockchain can help ensure that coffee growers are given fair payments for their crops, and are maintaining sustainability practices.

Today’s computers have the equivalent of human eyes, ears, mouths and limbs. Why not noses as well?

Phil Renaud, executive director of The Risk Institute at The Ohio State University’s Fisher College of Business, runs down the level of risk to supply chains created by relationships with third parties — and relates how a certain type of third party can help to mitigate it.

Al Guarnieri, partner in the law firm of Parker Poe, details how the COVID-19 pandemic has impacted the planning efforts of manufacturers in the short, medium and long term.

Brad Simmons, managing partner with KAI Design, speculates about the form that the office of the future will take, to accommodate the need for social distancing as well as permanent remote workers.

For many years, pharmaceutical companies have struggled to track products through the supply chain. This drawback has made it easy for counterfeiters to introduce fake drugs into the market.